MCM
FENC icon

MAI Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

MAI Capital Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$111 Buy
+18
New +$139 ﹤0.01% 4739
2025
Q1 		– Sell
-200
Closed -$1.26K – 3488
2024
Q4 		$1.26K Buy
+200
New +$1.02K ﹤0.01% 3137

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

MAI Capital Management's FENC Position: Q1 2026 in Review

MAI Capital Management opened a new position in Fennec Pharmaceuticals (FENC) in Q1 2026: 18 shares worth $111. The stake represents ﹤0.01% of the portfolio and ranks #4739 among its holdings. This is a return to the name: MAI Capital Management previously reported a position in FENC as recently as Q4 2024.

MAI Capital Management first reported a position in FENC in Q4 2024 and has held it in 2 quarters since. The position peaked at $1.26K in Q4 2024. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • MAI Capital Management held 18 shares of Fennec Pharmaceuticals worth $111 as of Q1 2026.
  • Fennec Pharmaceuticals was a new MAI Capital Management position in Q1 2026.
  • Fennec Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4739 holding.
  • MAI Capital Management first reported a position in Fennec Pharmaceuticals in Q4 2024 and has held it in 2 quarters since.
  • MAI Capital Management's Fennec Pharmaceuticals position peaked at $1.26K in Q4 2024.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.